1 / 6

Gouty Arthritis Therapeutics Development Pipeline Review H1 2015

This report gives extensive data on the restorative improvement for Gouty Arthritis (Gout), complete with relative examination at different stages, therapeutics appraisal by medication target, system of activity (MoA), course of organization (RoA) and atom sort, alongside most recent overhauls, and included news and press discharges. It likewise audits key players included in the restorative advancement for Gouty Arthritis (Gout) and unique components on late-stage and suspended tasks.

RamonEMarshall01
Download Presentation

Gouty Arthritis Therapeutics Development Pipeline Review H1 2015

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Gouty Arthritis (Gout) - Pipeline Review, H1 2015 By RnRMarketResearch.com Publisher Name : Global Market Direct Date: 29-May-2015 No. of pages: 118 Single User License: US $2000 Browse more Reports on Arthritis Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/arthritis-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Gouty Arthritis (Gout) - Pipeline Review, H1 2015 This report gives extensive data on the restorative improvement for Gouty Arthritis (Gout), complete with relative examination at different stages, therapeutics appraisal by medication target, system of activity (MoA), course of organization (RoA) and atom sort, alongside most recent overhauls, and included news and press discharges. It likewise audits key players included in the restorative advancement for Gouty Arthritis (Gout) and unique components on late-stage and suspended tasks. The report improves choice making capacities and help to make powerful counter procedures to increase game changer. It reinforces R&D pipelines by recognizing new targets and MOAs to create first-in-class and best-in-class items. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Gouty Arthritis (Gout) - Pipeline Review, H1 2015 Companies Discussed/Mentioned in this Research : arhalofenate, CTX-4430, diacerein, DLX-2323, DLX-2681, Fc-Alpha-1 Antitrypsin, FcAAT-2, FcAAT-3, febuxostat, febuxostat XR, AstraZeneca PLC, Celtaxsys, Inc., CymaBay Therapeutics, Inc., Delenex Therapeutics AG, Immune Response BioPharma, Inc., IOmet Pharma, JW Pharmaceutical Corporation, Kissei Pharmaceutical Co., Ltd., LG Life Sciences, Ltd., Nimbus Therapeutics, LLC and many more Drugs Profile Discussed in this Research : IR-888, KUX-1151, LC-350189, lesinurad sodium, Monoclonal Antibody to Inhibit S100A9 Protein for Neurodegenerative Diseases, Chronic Inflammation and Autoimmune Disorders, NC-2500, ND-2110, ND-2158, ND-346, pegadricase, pegadricase, PL-4100, PN-XXXX, RDEA-3170, Recombinant Enzyme for Gout and Tumor Lysis Syndrome, REV-002, RLBN-1001 and many more ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Gouty Arthritis (Gout) - Pipeline Review, H1 2015 Scope For Gouty Arthritis (Gout) - Pipeline Review, H1 2015 • The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Gouty Arthritis (Gout) and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Gouty Arthritis (Gout) - Pipeline Review, H1 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout) • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Gouty Arthritis (Gout) - Pipeline Review, H1 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related